TX-MOUSER-ELECTRONICS
24.1.2022 20:12:08 CET | Business Wire | Press release
Mouser Electronics , Inc., the New Product Introduction (NPI) leader™ empowering innovation, is excited to partner with the DRAGON / PENSKE AUTOSPORT team for the ABB Formula E FIA World Championship series’ eighth season, which kicks off with double-header races at Diriyah E-Prix on January 28 and 29. The fourth consecutive season-opener at Diriyah gives fans two exciting night races just outside Saudi Arabia’s capital of Riyadh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005567/en/
Mouser is partnering with the DRAGON / PENSKE AUTOSPORT team throughout the 2021–22 ABB FIA Formula E World Championship racing season, in collaboration with TTI, Inc . and valued manufacturers Molex and KYOCERA AVX . This is the eighth-straight year that Mouser and Molex have sponsored Formula E racing.
Driver Sérgio Sette Câmara returns to the team to helm the No. 7 Penske EV-5 car, while Formula 1 reserve driver Antonio Giovinazzi joins the team to take the wheel of the No. 6 car. The new season serves up 16 races, including stops in Jakarta, Vancouver, and Seoul, plus increased car power and new race qualifying formats.
“Mouser is thrilled to team up with Molex, TTI and KYOCERA AVX to partner with DRAGON / PENSKE AUTOSPORT for the eighth year in a row,” said Todd McAtee, Vice President, Americas Business Development for Mouser Electronics. “Formula E’s focus on developing and incorporating the latest in electric vehicle technology resonates with Mouser, our customers, and our fans and followers. We wish Sette Câmara, Giovinazzi, and the team the best this season!”
"TTI is pleased to team up with Mouser in supporting this exciting sport and its spotlight on sustainable automotive technologies of the future,” said Mike Morton, TTI Chief Executive Officer.
“This new chapter of Formula E promises to continue the evolution of this thrilling sport and serves as a powerful showcase for its electric future,” said Fred Bell, Vice President of Global Distribution for Molex. “Mouser and Molex have been proud supporters since the inception of Formula E, and we wish the DRAGON / PENSKE AUTOSPORT team a safe and successful season.”
“We’re delighted to collaborate with Mouser, Molex, and TTI in our partnership with the DRAGON / PENSKE AUTOSPORT Formula E racing team for another exciting season,” said Alex Schenkel, KYOCERA AVX’s Senior Vice President of Global Sales.
The Formula E series features cars that are powered solely by electricity and represent a vision for the future of the motor sports industry, serving as a framework for research and development around zero-emission motoring. The Gen2 cars offer a huge step forward in electric vehicle racing technology, with maximum power of 250 kW and speeds up to 280 km/h. Racing is all about speed and endurance, and racing partnerships are an innovative way for Mouser to communicate its performance-driven business model and promote the newest technologies from its manufacturer partners.
Fans can cast a vote for Sette Câmara and Giovinazzi in FANBOOST , which allows fans to play an active role in influencing the outcome of the race. FANBOOST gives fans the opportunity to vote for their favorite driver and award them an extra boost of power during the race. The five drivers with the most FANBOOST votes are awarded a significant burst of power, which they can deploy in a 5-second window during the second half of the race. FANBOOST voting for the Diriyah E-Prix opens January 25 and is available up to 15 minutes into the race.
To learn more, visit https://www.mouser.com/formula-e/ .
For more Mouser news, visit https://www.mouser.com/newsroom/ .
As a global authorized distributor, Mouser offers the world’s widest selection of the newest semiconductors and electronic components — in stock and ready to ship™. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each of its manufacturer partners. To help speed customers’ designs, Mouser’s website hosts an extensive library of technical resources, including a Technical Resource Center , along with product data sheets, supplier-specific reference designs, application notes, technical design information, engineering tools and other helpful information.
Engineers can stay abreast of today’s exciting product, technology and application news through Mouser’s complimentary e-newsletter. Mouser’s email news and reference subscriptions are customizable to the unique and changing project needs of customers and subscribers. No other distributor gives engineers this much customization and control over the information they receive. Learn about emerging technologies, product trends and more by signing up today at https://sub.info.mouser.com/subscriber .
About Mouser Electronics
Mouser Electronics, a Berkshire Hathaway company, is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 5 million products from over 1,200 manufacturer brands. Mouser offers 27 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 630,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/ .
Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005567/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom